Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05598528Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Role: collaborator

NCT04150835Phase 4Unknown

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Role: collaborator

NCT04408261Phase 2Unknown

BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome

Role: collaborator

All 3 trials loaded